Case Report: Solitary adrenal metastasis from esophageal adenocarcinoma

IntroductionSolitary adrenal metastasis from a primary esophageal malignancy is relatively rare. While there are case reports of aggressive treatment with esophagectomy and adrenalectomy providing long-term survival, the treatment paradigm is not well defined. Complications from esophageal adenocarc...

Full description

Saved in:
Bibliographic Details
Main Authors: Riddhi Machchhar, Ahmed Dawood Al Mahrizi, Fatima Mossolem, Mariam Abdeen, Ujjwala Jain, Jyotibala Jain, Prashant Desai
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Medicine
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2025.1623443/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850102435488464896
author Riddhi Machchhar
Ahmed Dawood Al Mahrizi
Fatima Mossolem
Mariam Abdeen
Ujjwala Jain
Jyotibala Jain
Prashant Desai
author_facet Riddhi Machchhar
Ahmed Dawood Al Mahrizi
Fatima Mossolem
Mariam Abdeen
Ujjwala Jain
Jyotibala Jain
Prashant Desai
author_sort Riddhi Machchhar
collection DOAJ
description IntroductionSolitary adrenal metastasis from a primary esophageal malignancy is relatively rare. While there are case reports of aggressive treatment with esophagectomy and adrenalectomy providing long-term survival, the treatment paradigm is not well defined. Complications from esophageal adenocarcinoma and its treatment can significantly impact the patient’s quality of life and prognosis.Case presentationOur patient was treated with systemic therapy and, although he initially had a complete response, he later experienced local disease progression along with the development of additional metastatic sites. The patient began FOLFOX, a standard chemotherapy regimen for esophageal/gastric cancer. He experienced side effects such as fever, malaise, and constipation, which were symptomatically managed. Given these side effects, the patient’s FOLFOX regimen underwent a 25% dose reduction of the 5FU bolus. A PET/CT scan after three months showed a marked response to chemotherapy, with complete resolution of detectable disease. The patient reported fatigue, bone pain managed with Neulasta, nausea controlled with antiemetics, and neuropathy in his feet. The patient then began a new chemotherapy regimen with Taxol/Ramucirumab with dose modifications in response to side effects. Continued adjustments to the treatment and dosages were made for progressive side effects and the patient elected to receive palliative radiation to the esophagus, along with holistic supportive care. The treatment plan shifted to palliative care, focusing on quality of life, rather than curative, due to the complexities of his cancer.ConclusionWhile aggressive treatments may offer hope for a cure in select patients with isolated adrenal metastasis from esophageal cancer, the general approach should remain cautious, with systemic therapy as the first line of defense. This case highlights the need for careful selection to identify patients who may benefit from aggressive surgical treatment. Ongoing research and clinical trials are needed to better define treatment protocols and improve outcomes for this challenging patient group.
format Article
id doaj-art-cb927f58baca414d836b6cb80a6ce30e
institution DOAJ
issn 2296-858X
language English
publishDate 2025-07-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Medicine
spelling doaj-art-cb927f58baca414d836b6cb80a6ce30e2025-08-20T02:39:45ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-07-011210.3389/fmed.2025.16234431623443Case Report: Solitary adrenal metastasis from esophageal adenocarcinomaRiddhi Machchhar0Ahmed Dawood Al Mahrizi1Fatima Mossolem2Mariam Abdeen3Ujjwala Jain4Jyotibala Jain5Prashant Desai6Department of Graduate Medical Education, Ocean University Medical Center, Brick Township, NJ, United StatesFaculty of Medicine & Surgery, University of Malta, Msida, MaltaRowan University School of Osteopathic Medicine, Stratford, NJ, United StatesRowan University School of Osteopathic Medicine, Stratford, NJ, United StatesDepartment of Graduate Medical Education, Ocean University Medical Center, Brick Township, NJ, United StatesDepartment of Graduate Medical Education, Tufts University School of Medicine, Boston, MA, United StatesDepartment of Graduate Medical Education, Ocean University Medical Center, Brick Township, NJ, United StatesIntroductionSolitary adrenal metastasis from a primary esophageal malignancy is relatively rare. While there are case reports of aggressive treatment with esophagectomy and adrenalectomy providing long-term survival, the treatment paradigm is not well defined. Complications from esophageal adenocarcinoma and its treatment can significantly impact the patient’s quality of life and prognosis.Case presentationOur patient was treated with systemic therapy and, although he initially had a complete response, he later experienced local disease progression along with the development of additional metastatic sites. The patient began FOLFOX, a standard chemotherapy regimen for esophageal/gastric cancer. He experienced side effects such as fever, malaise, and constipation, which were symptomatically managed. Given these side effects, the patient’s FOLFOX regimen underwent a 25% dose reduction of the 5FU bolus. A PET/CT scan after three months showed a marked response to chemotherapy, with complete resolution of detectable disease. The patient reported fatigue, bone pain managed with Neulasta, nausea controlled with antiemetics, and neuropathy in his feet. The patient then began a new chemotherapy regimen with Taxol/Ramucirumab with dose modifications in response to side effects. Continued adjustments to the treatment and dosages were made for progressive side effects and the patient elected to receive palliative radiation to the esophagus, along with holistic supportive care. The treatment plan shifted to palliative care, focusing on quality of life, rather than curative, due to the complexities of his cancer.ConclusionWhile aggressive treatments may offer hope for a cure in select patients with isolated adrenal metastasis from esophageal cancer, the general approach should remain cautious, with systemic therapy as the first line of defense. This case highlights the need for careful selection to identify patients who may benefit from aggressive surgical treatment. Ongoing research and clinical trials are needed to better define treatment protocols and improve outcomes for this challenging patient group.https://www.frontiersin.org/articles/10.3389/fmed.2025.1623443/fullesophageal adenocarcinomaadrenal metastasissystemic therapyFOLFOXpalliative care
spellingShingle Riddhi Machchhar
Ahmed Dawood Al Mahrizi
Fatima Mossolem
Mariam Abdeen
Ujjwala Jain
Jyotibala Jain
Prashant Desai
Case Report: Solitary adrenal metastasis from esophageal adenocarcinoma
Frontiers in Medicine
esophageal adenocarcinoma
adrenal metastasis
systemic therapy
FOLFOX
palliative care
title Case Report: Solitary adrenal metastasis from esophageal adenocarcinoma
title_full Case Report: Solitary adrenal metastasis from esophageal adenocarcinoma
title_fullStr Case Report: Solitary adrenal metastasis from esophageal adenocarcinoma
title_full_unstemmed Case Report: Solitary adrenal metastasis from esophageal adenocarcinoma
title_short Case Report: Solitary adrenal metastasis from esophageal adenocarcinoma
title_sort case report solitary adrenal metastasis from esophageal adenocarcinoma
topic esophageal adenocarcinoma
adrenal metastasis
systemic therapy
FOLFOX
palliative care
url https://www.frontiersin.org/articles/10.3389/fmed.2025.1623443/full
work_keys_str_mv AT riddhimachchhar casereportsolitaryadrenalmetastasisfromesophagealadenocarcinoma
AT ahmeddawoodalmahrizi casereportsolitaryadrenalmetastasisfromesophagealadenocarcinoma
AT fatimamossolem casereportsolitaryadrenalmetastasisfromesophagealadenocarcinoma
AT mariamabdeen casereportsolitaryadrenalmetastasisfromesophagealadenocarcinoma
AT ujjwalajain casereportsolitaryadrenalmetastasisfromesophagealadenocarcinoma
AT jyotibalajain casereportsolitaryadrenalmetastasisfromesophagealadenocarcinoma
AT prashantdesai casereportsolitaryadrenalmetastasisfromesophagealadenocarcinoma